1. Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis
- Author
-
Erik Lundgren, P.I. Ohlsson, Yukio Ando, Gösta Holmgren, Ole B. Suhr, Karin Andersson, Anders Olofsson, and Masayuki Ando
- Subjects
endocrine system ,medicine.medical_specialty ,biology ,Amyloid ,Chemistry ,Amyloidosis ,Clinical Biochemistry ,nutritional and metabolic diseases ,General Medicine ,medicine.disease ,Biochemistry ,Asymptomatic ,Pathogenesis ,Transthyretin ,Amyloid Neuropathy ,Amyloid disease ,Endocrinology ,Internal medicine ,medicine ,biology.protein ,medicine.symptom ,Polyneuropathy - Abstract
Background For all forms of amyloidosis, the amyloid-generating mechanism is unknown. Familial amyloidotic polyneuropathy type I is caused by a variant transthyretin (TTR Met-30). As electrospray ionization mass spectrometry (ESI-MS) discloses both thiol-conjugated and -unconjugated forms of wild-type and variant TTR, we wanted to investigate the relationship between TTR conjugation and clinically overt amyloid disease. Methods Plasma from 35 individuals (12 symptomatic TTR Met-30 carriers, nine asymptomatic and 14 healthy control subjects) were analysed using ESI-MS. Results The total TTR concentration was significantly lower in symptomatic TTR Met-30 carriers than in control subjects. An increased percentage of conjugated TTR Met-30 was found in symptomatic carriers compared with asymptomatic, whereas the percentage conjugated wild-type TTR was similar for control subjects, asymptomatic and symptomatic TTR Met-30 carriers. Conclusion The finding of a decreased ratio of unconjugated to conjugated TTR Met-30 in plasma samples from symptomatic TTR Met-30 carriers indicates that thiol conjugation of TTR could be involved in amyloid formation.
- Published
- 1998
- Full Text
- View/download PDF